Molecular Imaging: Page 130

MBI lexicon enhances radiologist interpretation

By Kate Madden Yee

Monday, December 2 | 12:45 p.m.-1:15 p.m. | BR230-SD-MOB1 | Lakeside, BR Community, Station 1Understanding the predictive features of molecular breast imaging (MBI) lexicon descriptors improves radiologist interpretation of these exams and allows for appropriate management and follow-up of patients, according to research to be presented Monday afternoon.

November 4, 2019

PET/MRI sheds light on cerebral vascular risk factors

By Wayne Forrest

PET/MRI scans show middle-aged adults with high vascular risk factors have less whole-brain volume by the time they reach their late 60s, but their lifestyle and physical characteristics do not influence beta-amyloid accumulation, according to a study published online November 4 in JAMA Neurology.

November 3, 2019

Deep learning detects bone metastases on PET/CT

By Erik L. Ridley

Sunday, December 1 | 10:45 a.m.-10:55 a.m. | SSA16-01 | Room S505ABA deep-learning system can yield promising results for identifying and annotating bone metastases on PET/CT image data, according to this talk by researchers from Japan.

November 3, 2019

Deep-learning model characterizes PET/CT findings

By Erik L. Ridley

An artificial intelligence algorithm shows a promising level of accuracy for identifying normal and abnormal results on FDG-PET/CT exams, and it could potentially help radiologists avoid missed findings, according to research published online October 28 in the Journal of Digital Imaging.

October 31, 2019

Lantheus posts lower Q3 results

By AuntMinnie.com staff writers

Lantheus Medical Imaging parent company Lantheus Holdings posted lower revenues and net income for its third quarter of 2019.

October 30, 2019

CEDM, MBI outperform MRI for breast cancer staging

By Kate Madden Yee

Contrast-enhanced digital mammography (CEDM) and molecular breast imaging (MBI) are comparable to breast MRI when it comes to identifying breast cancer, but CEDM and MBI outperform breast MRI when it comes to treatment staging, according to a study published online October 29 in Radiology.

October 30, 2019

Navidea highlights rheumatoid arthritis results

By AuntMinnie.com staff writers

Radiopharmaceutical developer Navidea Biopharmaceuticals said that interim analysis of an ongoing phase IIB study shows positive results from using its technetium-99m tilmanocept radiopharmaceutical in patients with rheumatoid arthritis.

October 29, 2019

Hermes gets FDA clearance for radiation dose software

By AuntMinnie.com staff writers

Hermes Medical Solutions has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Voxel Dosimetry software for estimating radiation dose in nuclear medicine studies.

October 22, 2019

Is PET really necessary to predict oncoming Alzheimer's?

By Wayne Forrest

Can a person's progression from mild cognitive impairment to Alzheimer's disease be reliably predicted without PET imaging? A new study published online October 18 in the Journal of Nuclear Medicine lists several nonimaging methods that could offer a better prognosis than the modality.

October 20, 2019

NRC accepts Shine's operating application

By AuntMinnie.com staff writers

The U.S. Nuclear Regulatory Commission (NRC) has accepted an operating license application from Shine Medical Technologies for the company's planned medical isotope production facility in Janesville, WI.

October 14, 2019

ImaginAb signs collaboration deal with 3 firms

By AuntMinnie.com staff writers

Imaging agent developer ImaginAb has signed a collaboration agreement with pharmaceutical companies AstraZeneca, Pfizer, and Takeda Pharmaceutical to further the clinical development of its CD8 PET technology.

October 14, 2019

Shine forms therapeutics division

By AuntMinnie.com staff writers

Medical isotope firm Shine Medical Technologies has launched Shine Therapeutics, a new division that will target the market for therapeutic isotopes.

October 13, 2019

Previous Page

Page 130 of 614

Next Page